

Biomarkers in diagnosis and progression of castration-resistant prostate cancer

Poster Session 36

Sunday, 26 March
12:15 - 13:45

Location: Room Stockholm, North Hall (Level 1)

Chairs: I.T.R. Cavarretta, Milan (IT)
C. Jeronimo, Porto (PT)
H.G. Lilja, New York (US)

Aims and objectives of this session

Use of validated prostate cancer biomarkers is important for selection of patients who risk developing aggressive disease and also for monitoring castration therapy resistance. Novel approaches to analyze markers in multifocal prostate cancer will be presented.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*481

Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death

By: [Na R.](#)¹, [Zheng S.L.](#)², [Han M.](#)³, [Yu H.](#)², [Jiang D.](#)², [Shah S.](#)², [Ewing C.](#)³, [Zhang L.](#)³, [Novakovic K.](#)⁴, [Petkewicz J.](#)², [Gulukota K.](#)⁵, [Helseth D.](#)⁵, [Quinn M.](#)², [Humphries E.](#)³, [Wiley K.](#)³, [Isaacs S.](#)³, [Wu Y.](#)¹, [Liu X.](#)², [Zhang N.](#)¹, [Wang C-H.](#)², [Khandekar J.](#)⁵, [Hulick P.](#)⁶, [Shevrin D.](#)⁶, [Cooney K.](#)⁷, [Shen Z.](#)¹, [Partin A.](#)³, [Carter H.B.](#)³, [Carducci M.](#)⁸, [Eisenberger M.](#)⁸, [Denmeade S.](#)⁸, [McGuire M.](#)⁴, [Walsh P.](#)³, [Helfand B.](#)⁴, [Brendler C.](#)⁴, [Ding Q.](#)¹, [Xu J.](#)², [Isaacs W.](#)³

Institutes:¹Huashan Hospital, Fudan University, Dept. of Urology, Shanghai, China, ²NorthShore University HealthSystem, Program for Personalized Cancer Care, Evanston, United States of America, ³Johns Hopkins University School of Medicine, Dept. of Urology and The James Buchanan Brady Urologic Institute, Baltimore, United States of America, ⁴NorthShore University HealthSystem, Dept. of Surgery, Evanston, United States of America, ⁵NorthShore University HealthSystem, Center for Molecular Medicine, Evanston, United States of America, ⁶NorthShore University HealthSystem, Dept. of Medicine, Evanston, United States of America, ⁷University of Utah, Dept. of Internal Medicine, Salt Lake City, United States of America, ⁸Johns Hopkins Medical Institutions, Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States of America

*482

Comprehensive molecular dissection of multi-focal prostate cancer and concomitant lymph node metastasis: Implications for tissue based prognostic biomarkers

By: [Salami S.](#)¹, [Hovelson D.](#)², [Mathieu R.](#)³, [Kaplan J.](#)², [Susani M.](#)⁴, [Rioux-Leclercq N.](#)⁵, [Shariat S.](#)³, [Tomlins S.](#)², [Palapattu G.](#)¹

Institutes:¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, ³Medical University Vienna, Dept. of Urology, Vienna, Austria, ⁴Medical University Vienna, Dept. of Pathology, Vienna, Austria, ⁵Rennes University Hospital, Dept. of Pathology, Rennes, France

483

A genomic analysis of metastases-prone localized prostate cancer in a European high-risk population

By: [Van Den Broeck T.](#)¹, [Gevaert T.](#)¹, [Prekovic S.](#)², [Ong K.](#)³, [Tosco L.](#)¹, [Moris L.](#)², [Smeets E.](#)², [Lehrer J.](#)³, [Haddad Z.](#)³, [Helsen C.](#)², [Margrave J.](#)³, [Van Poppel H.](#)¹, [Everaerts W.](#)¹, [Erho N.](#)³, [Buerki C.](#)³, [Davicioni E.](#)³, [Joniau S.](#)¹, [Claessens F.](#)²

Institutes:¹UZ Leuven, Dept. of Urology, Leuven, Belgium, ²KU Leuven, Laboratory of Molecular Endocrinology, Leuven, Belgium, ³GenomeDx, GenomeDx Biosciences, Vancouver, Canada

484

Analysing circulating tumour cells with epithelial and mesenchymal features for prostate cancer prognosis

By: Xu L.¹, Mao X.², Guo T.², Chan P.Y.³, Shaw G.⁴, Hines J.⁴, Wang Y.², Oliver T.², Ahmad A.⁵, Berney D.², Shamash J.³, Lu Y-J.²

Institutes:¹Barts Cancer Institute, Center for Molecular Oncology, London, United Kingdom, ²UnZhongshan Hospital Fudan University, Dept. of Urology, Shanghai, China, ³Barts Cancer Institute, Centre for Molecular Oncology, London, United Kingdom, ⁴Barts Health NHS, Dept. of Medical Oncology, London, United Kingdom, ⁵Barts Health NHS, Dept. of Urology, London, United Kingdom, ⁶Wolfson Institute of Preventive Medicine, Centre for Cancer Prevention, London, United Kingdom

485

Decipher test impacts decision-making among patients considering adjuvant and salvage treatment following radical prostatectomy: Interim results from the multicenter prospective PRO-IMPACT study

By: Gore J.¹, Du Plessis M.², Santiago-Jimenez M.³, Yousefi K.³, Thompson D.⁴, Karsh L.⁵, Lane B.⁶, Franks M.⁷, Chen D.⁸, Bandyk M.⁹, Bianco Jr. F.¹⁰, Brown G.¹¹, Clark W.¹², Kibel A.¹³, Kim H.¹⁴, Lowrance W.¹⁵, Manoharan M.¹⁶, Maroni P.¹⁷, Perrapato S.¹⁸, Sieber P.¹⁹, Trabulsi E.²⁰, Waterhouse R.²¹, Davicioni E.²², Lotan Y.²³, Lin DW¹

Institutes:¹University of Washington, Seattle Cancer Care Alliance, Seattle, United States of America, ²GenomeDx Biosciences, Clinical Development, Vancouver, Canada, ³GenomeDx Biosciences, Dept. of Biostatistics, Vancouver, Canada, ⁴Emmes Canada, Dept. of Biostatistics, Burnaby, Canada, ⁵The Urology Center of Colorado, Dept. of Urology, Colorado, United States of America, ⁶Spectrum Health Medical Group, Dept. of Urology, Grand Rapids, United States of America, ⁷Virginia Urology, Dept. of Urology, Richmond, United States of America, ⁸Fox Chase Cancer Center, Surgical Oncology, Philadelphia, United States of America, ⁹Lakeland Regional Cancer Center, Dept. of Urology, Lakeland, United States of America, ¹⁰Nova Southeastern University, Urological Research Network, Miami, United States of America, ¹¹Delaware Valley Urology, LLC, Dept. of Urology, Voorhees, United States of America, ¹²Alaska Clinical Research Center, Dept. of Urology, Anchorage, United States of America, ¹³Brigham and Womens Hospital, Dept. of Urology, Boston, United States of America, ¹⁴Cedars-Sinai Medical Center, Dept. of Urology, Los Angeles, United States of America, ¹⁵University of Utah, Huntsman Cancer Institute, Salt Lake City, United States of America, ¹⁶University of Miami, Miller School of Medicine, Miami, United States of America, ¹⁷University of Colorado, Anschutz Medical Campus, Aurora, United States of America, ¹⁸University of Vermont Medical Center, Dept. of Urology, Burlington, United States of America, ¹⁹Lancaster Urology, Dept. of Urology, Lancaster, United States of America, ²⁰Thomas Jefferson University, Sidney Kimmel Medical College, Philadelphia, United States of America, ²¹Carolina Urology Partners, Dept. of Urology, Gastonia, United States of America, ²²GenomeDx Biosciences, Bioinformatics, San Diego, United States of America, ²³UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America

486

The occurrence and therapeutic consequences of androgen receptor copy number gain in prostate cancer patients using Droplet Digital PCR

By: Buelens S.¹, Claeyts T.¹, Kumps C.¹, Dhondt B.¹, Poelaert F.¹, Nurten Y.², Vynck M.³, Thas O.³, Ost P.⁴, Vandesompele J.², Lumen N.¹

Institutes:¹Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ²Ghent University, Dept. of Pediatrics and Medical Genetics, Ghent, Belgium, ³Ghent University, Dept. of Mathematical Modelling, Statistics and Bio-Informatics, Ghent, Belgium, ⁴Ghent University Hospital, Dept. of Radiation Oncology, Ghent, Belgium

487

Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling

By: Morgan T.¹, Singhal U.¹, Wang Y.¹, Henderson J.¹, Niknafs Y.², Qiao Y.², Taichman R.³, Zaslavsky A.¹, Feng F.⁴, Palapattu G.¹, Chinnaiyan A.², Tomlins S.²

Institutes:¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, ³University Of Michigan, School of Dentistry, Ann Arbor, United States of America, ⁴University of California San Francisco, Dept. of Radiation Oncology, San Francisco, United States of America

488

Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event selecting for FKBP4 driven castration resistance

By: Gsponer J.², Quintavalle C.², Müller D.¹, Lorber T.², Juskevicius D.², Lenkiewicz E.³, Zellweger T.⁴, Barrett M.³, Bubendorf L.², Ruiz C.², Rentsch C.¹

Institutes:¹University Hospital Basel, Dept. of Urology, Basel, Switzerland, ²University Hospital Basel, Institute for Pathology, Basel, Switzerland, ³Mayo Clinic Arizona, Dept. of Research, Scottsdale, United States of America, ⁴St. Claraspital, Dept. of Urology, Basel, Switzerland

490

Cell free DNA methylation markers as predictors of treatment response and prognosis for castration-resistant prostate cancer

By: Hendriks R.¹, Dijkstra S.¹, Smit F.², Vandersmissen J.², Van De Voorde H.², Mulders P.¹, Van Oort I.¹, Van Criekinge W.³, Schalken J.¹

Institutes:¹Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²MDxHealth, Dept. of Research and Development, Irvine, United States of America, ³Ghent University, Dept. of Statistics and Bio-Informatics, Ghent, Belgium

491

Expression of neuropilin 2 as predictor for tumour-related death in patients with prostate cancer

By: Borkowetz A.¹, Toma M.², Füssel S.¹, Erdmann K.¹, Hoenscheid P.², Froehner M.¹, Muders M.², Wirth M.¹

Institutes:¹TU Dresden, Dept. of Urology, Dresden, Germany, ²TU Dresden, Dept. of Pathology, Dresden, Germany

492

Calcium signaling remodeling as a predictive factor of systemic recurrence after radical prostatectomy

By: Perrouin Verbe M.A.¹, Talagas M.², Garlantezec R.³, Schoentgen N.⁴, Uguen A.², Doucet L.², Rosec S.⁵, Nicot M.C.², Gobin E.², Marcorelles P.², Fournier G.⁴, Valeri A.⁴, Mignen O.⁶

Institutes:¹Pitié Salpêtrière Academic Hospital, Dept. of Urology, Paris, France, ²Brest University Hospital, Dept. of Pathology, Brest, France, ³University Rennes 1, INSERM U1085-IRSET, Rennes, France, ⁴Brest University Hospital, Dept. of Urology, Brest, France, ⁵Brest University Hospital, INSERM U 1412, Centre D'Investigation Clinique, Brest, France, ⁶University of Brest, INSERM U 1078, Brest, France

13:30 - 13:37

Circulating tumor cells in prostate cancer

H.G. Lilja, New York (US)